 early cancer diagnosis,2
APE1,2
 vaccine,4
 Outcome,5
 Sepsis,2
PD-1,16
 irAE,2
 Feature selection,2
Brain,3
 Neutropenia,3
 real-world evidence,3
 migration,28
 genetic markers,2
 neutrophil-to-lymphocyte ratio,4
 predictive,2
 miR-498,2
Cytology,2
Deep learning,6
Lipid,2
 nanoparticles,12
 Radioimmunotherapy,2
 quality of care,2
 OV,2
 Glycemic index,2
 Gene delivery,2
 Hyaluronic acid,4
 tumor,21
 Non-small cell,2
 cell block,2
 diabetes mellitus,2
 immune system,3
Anti-PD-1/PD-L1,2
 Pulmonary delivery,2
 literature review,2
 Interstitial pneumonia,2
 HOTAIR,2
 screening,11
 Early detection,2
 macrophage,4
 cancer immunology,2
 imatinib,2
 clinical outcome,2
 GC-MS,2
 surveillance,3
 Triple-negative breast cancer,3
 TILs,4
 NSCLC ,2
 lung squamous cell carcinoma ,2
 Covid-19,2
 gene expression,11
 UCEC,3
 next generation sequencing,9
Akt,2
 differentially expressed genes,4
Arsenic,7
 Radon,4
 Immunology,3
A549,9
Acquired resistance,2
 esophagus,2
 autophagy,23
 non-small-cell lung cancer,74
 Dyslipidemia,2
 c-Myc,5
Base excision repair,2
 treatment outcome,3
 supportive care,6
 Wnt signaling pathway,2
Cigarette smoking,2
 cell invasion,2
CD4,2
cancer therapy,2
 Gamma knife radiosurgery,3
Atezolizumab,7
 proliferation,56
 Colon cancer,4
 recurrence,14
 Epigenetics,3
 pediatrics,2
 adjuvant chemotherapy,5
 HCC827,2
African American,3
 Tumor metastasis,2
bronchoscopy,6
GSK3β,2
brain,2
 small cell lung cancer,25
 Platelet-derived growth factor,2
 Chronic obstructive pulmonary disease,3
 nanoparticle,3
 CEA,3
 Single nucleotide polymorphism,2
 central tumor,2
 Squamous cell lung carcinoma,2
Gallbladder cancer,2
 Low-dose computed tomography,2
1 therapy,2
 PTV,2
 T790M,3
 TAMs,2
ATP,3
Osimertinib,2
 lymphoma,4
 symptom burden,2
U-VATS,2
immunotherapy,14
Lung cancer screening,4
 Recurrence-free survival,3
 asthma,8
 India,3
CCR7,2
 cyclin D1,2
 transcription factor,5
 dose-response,2
 Predictor,3
 Salivary gland,2
Caregivers,2
 qualitative research,3
 thromboelastography,2
 mutations,7
 Neutropenia-related hospitalization,2
 mouse,2
 Exosomes,6
 phytochemicals,2
 comorbidity,3
 Chemoprevention,2
-1,2
 1,2
 Non-small-cell lung,3
 Programmed death ligand 1,3
 hypoxia-inducible factor 1α,2
 adenocarcinoma,8
PTEN,2
Abemaciclib,2
 hypoxia,8
 Cardiotoxicity,5
DNA sequencing,2
 radiology,4
 gene mutation,2
 Signature,2
 CDDP,2
 programmed cell death 1,2
Kaplan-Meier analysis,2
PFS,2
AKT,16
 cytopathology,2
 respiratory,3
 Traditional Chinese Medicine,2
 dexamethasone,2
Immune checkpoint inhibitor,8
Differentially expressed genes,2
 Lung segmentectomy,2
 photodynamic therapy,3
 lung function,4
Epidemiology,4
Pembrolizumab,2
 surgical outcome,2
 solitary pulmonary nodule,3
 Cancer therapy,3
 gene editing,2
MRI,4
COVID-19 pandemic,2
 Next-generation sequencing,13
Immune checkpoint inhibitors,6
 glycans,3
 Prognostic model,2
 SMARCA4,2
 Flow cytometry,3
SNP,3
 mortality,24
Glycolysis,2
ATM,2
 integrin αvβ3,2
ERα,2
 Tumor growth rate,2
 squamous cell carcinoma,9
 miRNA dysregulation,2
 cetuximab,7
malignant pleural effusion,2
 Neoplasm,2
 Mycobacterium tuberculosis,2
 EGFR-TKI,8
 Treatment,12
 particulate matter,2
 Malignant pleural mesothelioma,5
 Endoplasmic reticulum stress,3
 immune checkpoint inhibition,4
Alectinib,5
 T-type calcium channel,2
 sensitivity,4
 Iron,2
 Pleura,3
 young patients,2
 Hodgkin lymphoma,3
DNA methylation,13
 trajectory,2
 hepatocarcinoma,2
Durvalumab,6
 PI3K/AKT pathway,2
air pollution,2
Notch pathway,2
Nrf2,2
 esophageal cancer,9
 respiratory infections,2
Meta-analysis,6
 Lobectomy,5
 TNM stage,2
 water pipe,2
 Lung resection,4
 ferroptosis,6
TCP,2
Breast,2
Adaptive radiotherapy,2
 Cancer du sein,2
 Liver cancer,4
 Small cell lung cancer,15
 optical coherence tomography,2
 risk factor,5
 RNA-binding protein,2
 Inflammatory response,2
PDX,2
 artificial intelligence,2
 live cell imaging,2
PET,11
 Metastases,5
MET,2
 Mendelian randomization,3
 miRNA-143-3p,2
 lung,26
 DFT,2
Malignant mesothelioma ,2
 Cytokines,2
 purinergic signaling,2
 immune-related adverse event,6
 Elderly,4
 thyroid transcription factor-1,5
 mitochondria,5
 First-line therapy,2
 Random Forest,2
ALI,2
 relative biological effectiveness,2
 receptor tyrosine kinase,2
 Combination treatment,2
 Embolization,2
 S-1,3
Circulating tumor DNA ,2
 pneumothorax,2
 SOX2,6
 lung surgery,3
 β-Carboline,3
 traditional Chinese medicine,4
 exosome,12
 BLCA,2
 variational method,2
 intensity-modulated proton therapy,2
 liquid-based cytology,2
lung,3
 stomach and duodenum,2
Anti-inflammatory agents,2
 siRNA delivery,2
 metabolism,6
anxiety,2
 virtual screening,4
 Senescence,2
 lung adenocarcinoma,115
 symptom management,2
 checkpoint inhibitor,7
 Targeted therapy,20
etoposide,2
ICAM-1,4
 febrile neutropenia,4
 Older adults,5
 multidrug resistance,2
 Cancer,38
 Real-world evidence,3
 second primary tumor,2
 immune response,3
 Complication,3
Anti-angiogenesis,2
 pain,3
 Glutathione,2
Fluorodeoxyglucose F18,2
 nicotine,2
 mucinous,2
 Epidermal growth factor receptor tyrosine kinase inhibitors,2
 RECIST,2
 androgen receptor,3
 pathology,7
 multimorbidity,2
PD-1/PD-L1,3
 Chronic obstructive pulmonary disease ,2
 mTOR inhibitor,2
 Distress,2
 Predictive preventive personalised medicine ,2
 molecular targeted therapy,2
 Predictive factors,2
Apoptosis,45
 ACC,2
 receptors,3
 diagnostic biomarker,2
 network meta-analysis,3
 diffuse alveolar damage,2
Anemia,3
Efficacy,3
 T cells,5
 Simulation,2
ARID1A,2
 Obesity,4
 colorectal neoplasms,2
 surgical oncology,2
Adenosine,2
 haematology ,2
 hospitalization,3
ALK rearrangement,5
 Non-smokers,2
lung neoplasms,2
 triple negative breast cancer,2
 Forecasting,2
 Cytokine storm,3
diagnosis,5
NLR,2
 ceRNA,6
 CT,8
 PET,8
 Ferroptosis,2
 Prostate cancer,17
 chest,2
 circulating tumor cell ,2
 ROS1,9
 kidney renal clear cell carcinoma,2
Checkpoint inhibitors,4
hydroxymethyl,2
Definitive chemoradiotherapy,2
 palbociclib,2
PET/CT,3
 Solitary pulmonary nodule,4
Bronchoscopy,16
 DOX,2
 tobacco control,2
 MTT,3
 microbiome,5
 long non-coding RNA,5
 Denosumab,3
emergency department,2
Chemosensitivity,2
 stomach adenocarcinoma,2
 Classification,4
 mass spectrometry,3
 Medicare,3
 CS-CTH-PLGA-NPs,2
 Protocol,3
 anti-PD-1,4
efficacy,2
 AR,2
 allosteric,2
 Pulmonary function,2
adverse event,2
pyrene,2
 advanced non-small cell lung cancer ,2
 Cell cycle analysis,2
Acute myeloid leukemia,2
 Curcumin,2
 Mass spectrometry,3
 Systematic review,7
EGF,2
 genome-wide association study,2
 miRNA,15
 checkpoint inhibitors,2
 Older patients,3
 prognostic factors,2
 oropharynx,2
 chemoimmunotherapy,2
 Prevention,2
 Registry,3
 PARP1,2
 Pan-cancer analysis,2
 EGFR T790M,2
incl blood transfusion,2
Small-cell lung cancer ,3
Invasion,4
EGFR,41
 Pneumothorax,3
 Real-world,3
 hedgehog signaling,2
 epithelial-mesenchymal transition ,2
 microbiota,3
 Neuroendocrine tumors,2
colorectal cancer,3
 Prognostic,4
Adverse event,3
 Randomised controlled trial,2
 second primary cancer,2
 Occupational,2
 risk stratification,3
 Survival prediction,2
non-small-cell lung cancer,2
 XIST,2
 pulmonary delivery,2
epidermal growth factor receptor,5
 Hypofractionated radiotherapy,3
 cisplatin resistance,8
 radial endobronchial ultrasound,2
 medicinal plants,2
 pseudoprogression,5
 Whole exome sequencing,3
MPLCs,2
 thoracic surgical procedures,2
Clinical outcomes,2
Uniportal video-assisted thoracoscopic surgery ,2
 pulmonary fibrosis,2
Febrile neutropenia,2
 Histone methylation,2
ADMET,2
 melanoma,18
 synergistic effects,2
Cancer genomics,2
age,2
A549 cells,9
 cell cycle,12
 central nervous system metastases,2
 polymorphism,6
 prognostic factor,4
 Heart failure,4
GGO,4
 Tumor mutation burden,2
Bioinformatics,9
 Regulatory T cells ,2
 induced pluripotent stem cells,2
Thoracic surgery,2
 National cancer database,2
 [,2
 Psychological distress,2
CT scan,3
 target therapy,5
GLUT1,2
 Cholangiocarcinoma,2
 Relapse,3
AECOPD,2
 Iran,2
 convolutional neural network,4
 Early-stage lung cancer,2
 tumor growth,3
 Pembrolizumab,18
 thyroid cancer,4
 cell death,4
 molecular profiling,2
 postoperative care,2
 tumor immune microenvironment,7
 paraneoplastic,2
 Cancer of unknown primary,2
oncology,6
EGFR positive,2
 Mediastinoscopy,2
 database,2
 PD1,2
 renal cell carcinoma,5
 let-7,2
 prognostic biomarker,3
 Local recurrence,2
Clinical characteristics,2
 Computed Tomography,3
 subtype,2
 pleural effusion,5
 Serum amyloid A,2
 RBM10,2
 Interstitial lung disease,10
 imaging biomarker,3
 DNA repair,3
 EMT,17
Epithelial-mesenchymal transition ,2
 tumor escape,3
Cáncer de pulmón,2
 FISH,2
 radiation pneumonitis,2
 radiofrequency ablation,2
 intraoperative radiotherapy,2
 Proteomics,3
Bioinformatics analysis,2
 methylation,7
K-Ras,2
 G12C,2
 iPSCs,2
 Lipid metabolism,2
 PVT1,2
 Survivorship,7
 education,3
 Pancreatic ductal adenocarcinoma,2
 Pregnancy,2
 Postoperative pain,2
 p53,18
 Circulating tumor DNA,2
LASP1,2
 Stroke,3
GSEA,3
 inflammation,22
 second malignancy,2
 SUVmax,3
 efficacy,5
 sublobar resection,7
 Osteosarcoma,3
 UPLC-MS,2
 PD-L1 TPS,2
HIV,5
 IFD,2
 SNAI2,2
 idiopathic pulmonary fibrosis,11
 Thieno[3,2
 epithelial–mesenchymal transition,3
 Pancreatic cancer,5
CEA,3
 selenoprotein,2
 Performance status,4
 stereotactic ablative radiotherapy,2
 sarcoidosis,4
 Cohort,2
 U,2
 Transcriptome,2
 cell cycle arrest,7
 misdiagnosis,2
adenocarcinoma,5
 neuroendocrine tumors,2
 Oral administration,2
 papillary thyroid carcinoma,2
 imaging,12
 gene therapy,4
 Neoadjuvant immunotherapy,2
 thoracoscopy,2
 Cystic fibrosis,3
 herbal medicine,2
 Gastric cancer,9
 gut microbiome,2
 Hematopoietic stem cell transplantation,2
Esophageal neoplasms,2
 Hippo,3
 vinorelbine,3
Metastasis,3
5-FU,2
C-reactive protein,8
EGFR inhibitor,2
Epidermal growth factor receptor ,4
CTC,5
 FDG-PET,4
 cancer vaccine,2
 Sensitivity and specificity,2
 IC50,2
 ghrelin,2
 PARP,2
 pulmonary hypertension,5
 epigenetics,7
 Maintenance therapy,2
 Macrophages,3
 Hemoptysis,2
 mitochondrial function,2
 lactate dehydrogenase,4
 miR-204-3p,2
 SPARC,2
anaplastic lymphoma kinase,2
 lung cancer therapy,3
 Tumor mutational burden,2
 Radioresistance,2
AIDS,2
 T790M mutation,2
 Lung Cancer,12
 Polymorphism,3
 PAAD,3
 cytokine release syndrome,2
 radiosensitivity,3
 tumor-associated macrophages,3
 nonsmall cell lung cancer,12
Hematoma,2
Metastases,2
 metastatic breast cancer,3
 Pulmonary toxicity,2
 interleukin 6,2
 Survival analysis,6
 Thrombosis,2
 genomics,4
 hydroxychloroquine,2
 NMR,3
 metastatic cancer,3
 MERS-CoV,2
B cells,2
 prostate adenocarcinoma,2
cause of death,3
 host microbial interactions,2
Diagnosis,9
 ovarian cancer,10
 gender differences,4
 Chitosan,2
 miR-145-5p,2
 afatinib,5
 Therapeutic strategies,2
 cryobiopsy,2
 human lung adenocarcinoma,2
Nivolumab,2
 epidermal growth factor receptor mutation,3
 macrophages,7
 radiotherapy ,2
 Thoron,2
 SEER-Medicare,2
 predictor,2
 SPECT,3
 Oncogenes,2
 caspase,2
 extracellular vesicles ,2
 incidence,10
 Thoracotomy,2
imaging/CT MRI etc,2
Epidermal growth factor receptor,7
 Silver nanoparticles,2
 Metastatic breast cancer,3
 genetic susceptibility,2
 Hepatocellular carcinoma,7
 Granulocyte colony-stimulating factor,2
 cell signaling,2
 second-line chemotherapy,2
Health services research,2
 PD-1 inhibitor,7
 irradiation,2
 Ex vivo,2
 physical activity,5
 Lipid peroxidation,2
 small molecule,3
 Molecular dynamics,2
 Small cell carcinoma,4
 Tumor-infiltrating immune cells,2
 pathogenesis,3
 molecular mechanism,3
 Overall survival,25
 Pharmacokinetics,5
 IMRT,2
 oxidative stress,16
Japan,3
 nitric oxide,3
GATA6-AS1,2
 Immune-related adverse events ,3
Acute exacerbation,5
Accuracy,3
 rash,2
HMGB3,2
 gender,2
 programmed cell death 1 receptor,2
 Vascular endothelial growth factor,3
 biomarkers,21
Idiopathic pulmonary fibrosis,2
 ER stress,4
Radiomics,3
cfDNA,3
 Metastasectomy,4
 G8,2
 Immune infiltration,2
Clinicopathological features,3
apoptosis,9
 cisplatin,19
 Pneumonia,7
 Anti-cancer,2
 immunity,7
 in situ hybridization,2
 progastrin-releasing peptide,2
 Neuroendocrine neoplasms,2
 chemoresistance,9
 stereotactic ablative body radiotherapy,2
 gastric cancer,12
 epithelial-mesenchymal transition,12
 bone marrow,3
Colorectal carcinoma,2
 Adenocarcinoma,2
 DSS,2
HCC,2
ADC,3
 SHP2,3
 solid nodule,2
 Resistance,3
 Hsp90,2
 Cancer risk,2
 treatment,12
 distant metastasis,3
NMR,2
 Skin cancer,3
 markers,2
 pemetrexed,5
 Single port,2
 single-cell RNA sequencing,3
 readmission,2
 Microvesicles,2
 GSTP1,2
 Lung adenocarcinoma,50
 programmed death-ligand 1 ,2
 Clinical trial,4
 Anlotinib,2
 Stereotactic radiotherapy,2
 external quality assessment,2
Cell cycle arrest,3
 gene signature,3
STAS,2
chemoradiation,2
 antitumor agents,2
 glioblastoma multiforme,2
 MCP-1,2
 Toxicity,5
 lipidomics,2
 Tumor-associated macrophages,2
Anxiety,3
 Early detection of cancer,4
 Molecular Biology,3
 vascular invasion,2
 LIHC,2
Brain metastases,10
KIAA0101,2
 Non-small-cell lung carcinoma,2
 sequencing,2
 Neoplasm metastasis,7
artificial intelligence,3
 uveal melanoma,2
 molecular testing,7
LKB1,2
STING,2
 metastases,4
 heterogeneity,5
 stereotactic radiosurgery,4
 PD-L1 inhibitor,2
 Positron emission tomography ,2
 transplant,2
 programmed cell death-ligand 1,2
Drug resistance,4
 Locally advanced,2
 Microenvironment,2
Prostate cancer,2
Immunotherapy,13
 cancer-associated fibroblasts,3
Cell Biology,2
 bioinformatics analysis,4
Chemotherapy,22
 Expert consensus,2
 colorectal cancer,19
LC-MS/MS,2
 central airway obstruction,2
CTCs,4
 p21,2
Epigenetics,2
 programmed cell death-1 ,2
 lncRNA,15
 growth,6
 Laparoscopy,2
 metastatic lung tumor,2
 Ground-glass nodule,2
 cell apoptosis,3
 Hepatitis,2
 Pathology,6
 hub gene,2
 UHPLC-MS/MS,2
lactide-co-glycolide,2
 Epidermal growth factor receptor mutation,4
 Wuhan,2
PDT,2
 Durvalumab,2
 Tumor immune microenvironment,3
 glioblastoma,3
 infectious diseases,2
 Granzyme B,2
 STAT3,8
Angiosarcoma,3
 saudi arabia,2
 pneumonitis,7
 Oral,2
cisplatin prodrug,2
 Apoptosis,28
TKI,3
 preclinical,2
 neutrophil,3
 Pulmonary drug delivery,2
 anti-angiogenesis,3
 pharmacokinetics,6
 mRNA expression,2
 glioma,2
 Health literacy,2
 KEAP1,4
 lung neoplasm,6
 epithelioid hemangioendothelioma,2
 TAZ,3
 early detection,2
 BRAF,2
 pleural lavage cytology,2
 circRNA,3
 Visceral pleural invasion,3
Adenocarcinoma,19
 esophageal squamous cell carcinoma,3
SMM,2
 Efficacy,6
 Docetaxel,3
cancer stem cells,3
 Subtyping,2
chimeric antigen,2
head and neck cancer,2
 Prediction,2
 CD73,4
 Non-small-cell lung cancer ,2
 Metastasis,41
 RFA,2
 Tumorigenesis,6
 positron emission tomography-computed tomography,2
 zoledronic acid,2
 lung tumor,2
long non-coding RNAs,2
 epidermal growth factor receptor,21
 COX-2,2
 Circulating tumor cells ,3
 lung injury,3
EBUS,4
 bladder cancer,4
 immunometabolism,2
CCL2,4
 Diagnostics,2
EGFR mutations,3
 non–small cell lung cancer,8
 MM/GBSA,2
combination,3
 nonsmall cell lung cancer ,2
 metastatic colorectal cancer,3
bone metastases,2
 pyrotinib,2
 PDX,2
 survivin,4
bioinformatical analysis,2
Radiotherapy,2
 pulmonary metastasis,4
 The Cancer Genome Atlas,3
 ctDNA monitoring,2
 m,2
 chimeric antigen,2
 cytotoxic activity,2
 health policy,4
Aerobic glycolysis,2
 Quasi-ultrafine particles,2
 radiomics,20
 H-score,2
 Synchronous,2
 real-world data,4
 elderly patients,2
 minimally invasive surgery,2
 AKT,2
 miR-335-5p,2
 Response,2
 Cancer research,4
Advanced cancer,3
 circEPSTI1,2
CUL4B,2
 and End Results ,7
 oral cancer,2
 Non-Hodgkin lymphoma,2
 Dual inhibitors,2
canine,2
 hepatocyte growth factor,2
 combination treatment,3
 Salvage,2
Asphericity,2
2019-nCoV,5
Concurrent chemoradiotherapy,2
 germ cell tumor,2
 cytotoxic chemotherapy,2
 anticancer,3
 Europe,2
MET amplification,4
 TLG,2
 video-assisted,2
 EGFR tyrosine kinase inhibitors,2
 Migration,9
 ROS generation,4
 HBV,2
 circulating tumor DNA ,2
 Clinical trials,3
 Wnt,4
 mass spectrometry imaging,3
 induction chemotherapy,2
 Leptomeningeal carcinomatosis,2
 epidemiology,17
 retreatment,2
 implementation science,2
 HIF-1α,3
 Olaparib,3
 liposomes,2
 prevention,3
 prognostic marker,2
 Robotic,2
 Stem cell transplantation,2
 Non-Small Cell Lung Cancer,3
 Immunotherapy,67
 small-cell lung cancer,14
 Treatment planning,2
 Serum tumor markers,3
 Pulmonary tumor embolism,2
 Mutation,5
D-dimer,2
 driver mutations,2
 tobacco,4
 carcinoma,6
 postoperative complications,2
 dihydroartemisinin,2
 malignant progression,3
18F-fluorodeoxyglucose,2
 programmed death-ligand 1,6
 stem cells,2
 Correlation,2
 Particulate matter,2
 ZEB1,2
 risk,2
 Pronóstico,2
 first-line treatment,3
 mice,3
 hypertension,3
 Anticancer activity,2
 Genomics,3
 signaling,2
 Patent foramen ovale,2
 pulmonary disease,2
Adenoid cystic carcinoma,2
 immune checkpoint inhibitors,24
 Long noncoding RNA,2
 coronavirus,7
 stereotactic body radiotherapy ,4
 Multidisciplinary,5
 Coronavirus ,3
 selpercatinib,2
 marantic endocarditis,2
 Radiation therapy,6
 Respiratory diseases,3
 Tuberculosis,3
Computed Tomography,2
 mycosis fungoides,2
BRAF,6
 Tobacco,4
 aerobic glycolysis,2
 PD-1/PD-L1 inhibitors,2
 Vitamin D,2
 tumorigenicity,2
 oncology,22
 Outcomes,8
 Drug delivery,3
 segmentectomy,10
 molecular analysis,2
 Cytotoxicity,15
 outcome,4
 tumor biomarkers,3
 Nutrition,3
 tumor control probability ,2
 Geriatric oncology,5
 pathways,2
 Poly ,3
 respiratory cancer,4
 exome sequencing,2
 Cytokine,3
TKIs,3
 Multi-omics,2
 Mutations,2
 Radiobiology,2
AMPK,4
MDSCs,2
 Rectal cancer,2
 RET,3
 Comorbidity,2
 Plasma,2
lobectomy,2
 cancer stem cells,8
 spatial,2
 non-small cell,2
 Nasopharyngeal carcinoma,2
antioxidant,2
 modeling,2
 Metformin,4
MSI,2
 Liquid biopsy,9
 GPX4,2
 tyrosine kinase inhibitors ,2
 Coronavirus disease 2019,2
Cancer immunotherapy,4
 epirubicin,2
 cisplatin-resistance,2
 BRCA,2
 SABR,2
 MAPK,4
 exosomes,8
 postoperative radiotherapy,2
 Non-steroidal,2
 Organic anion transporting polypeptide,2
Ion channels,2
 lymphangiogenesis,2
 Cardiovascular disease,3
 proteomics,11
 TTA-A2,2
 miR-21,5
irAE,2
 chemotherapy,42
 Lung,21
Bcl-2,2
Adverse events,2
 Image processing,2
 radon,3
 Immunoassay,3
 tumor microenvironment,32
CYP1A1,2
 medication adherence,2
 circular RNA,4
 Radiology,3
 preoperative care,2
Cardiac toxicity,2
 mesenchymal stem cells,4
 epithelial-to-mesenchymal transition,2
 knockdown,2
Non-small-cell lung cancer,9
 Progression-free survival,2
 NSE,2
 Targeted therapies,2
 SOCS5,2
 Prediabetes,2
CDKN2A,2
 Therapy,4
 Osimertinib,16
 EBUS,2
 Thiols,2
LINC00511,2
TACE,3
 Pattern recognition,2
 systematic review,15
 multivariate analysis,2
Diagnostic marker,2
 Alectinib,5
 somatic mutation,2
 lymphocytes,3
 Mortality,23
 miR-149,2
 immune checkpoint inhibitor,19
DNA nanostructures,2
 drug evaluation,2
 neoplasm,7
 comorbidities,2
 Topotecan,2
 Low dose,2
 shared decision-making,4
 Extracellular vesicle,2
 Survival time,2
 Clinical studies,2
 Psycho-oncology,2
 USP7,4
 ramucirumab,3
 tumor heterogeneity,5
 Wnt/β-catenin,6
 Esophageal squamous cell carcinoma,2
 Epidemiology,21
 Quality of life,13
 early stage,4
 Race,2
 EGFR tyrosine kinase inhibitor ,2
 FOXP3,3
 PKM2,2
Cancer cachexia,3
 Epidermal growth factor ,2
 MicroRNA,3
 Metastatic colorectal cancer,2
 low-dose computed tomography,3
 IPF,2
adaptive immunity,2
 Deep inspiration breath hold,2
Biochemistry,3
 Molecular targeted therapy,2
 Chest CT,2
 lung inflammation,2
 lorlatinib,3
RT,3
 microsatellite instability,3
CT,14
 smoking cessation,5
 metastasis-associated lung adenocarcinoma transcript 1,3
 Ground glass nodule,2
 CTLA-4,2
 non-small cell lung carcinoma ,2
Anti-cancer,3
 chemotherapy resistance,4
 dendritic cells,6
 ethnicity,3
 Thymidylate synthase,2
 icotinib,2
 ILD,2
 tumor suppressor,5
 Specificity,2
 interventional pulmonology,3
 Risk factor,3
 single-nucleotide polymorphism,7
Advanced gastric cancer,2
 lung SBRT,3
ctDNA,6
 thrombosis,3
 renal cancer,2
 cholangiocarcinoma,2
 cancer immunotherapy,5
 transcription factors,2
 sarcopenia,3
 Gene silencing,2
 Tumour,2
 hemoptysis,3
 Diet,2
SBRT,7
Crizotinib,3
 DCIS,2
 nanotechnology,3
 clinicopathological characteristics,2
 immune escape,2
II,5
AI,2
 Exhaled breath condensate,2
 Programmed cell death 1,3
 Infectious disease,2
 Public health,2
 endobronchial ultrasound-guided transbronchial needle aspiration,2
 mass screening,3
 combination therapy,13
 validation,2
DR5,2
 liver hepatocellular carcinoma,2
 thoracotomy,2
 Esophagectomy,2
 Atorvastatin,3
 lung cancer detection,2
Chemoresistance,3
EVs,2
Afatinib,11
 PET/TC,2
 malignant mesothelioma,5
 TNM,5
 single-cell analysis,3
 Brachytherapy,2
 gene ontology,2
 paraneoplastic syndromes,2
 Tumor microenvironment,10
 Transplantation,3
 Deep learning,5
 immune checkpoint,3
 EGFR tyrosine kinase inhibitor,2
 Lymph node metastasis,4
 anti-inflammatory,2
CTLA-4,3
 Postoperative complication,2
 general practice,3
 miRNAs,4
 quiescence,2
 OAR,2
STAT3,3
 Stereotactic body radiation therapy,12
 PDL1,3
 X-ray computed,6
 mediastinal lymphadenopathy,2
 pneumonia,15
 cancer imaging,2
Australia,3
 distress,3
 training,2
 angiogenesis inhibitors,2
 fine-mapping,2
 survival outcome,2
 NGS,6
 Pulmonary neoplasms,2
 Molecular biology,5
 cytokine,2
 staging,6
 neoantigen,4
Lung function,2
 cancer risk,2
clinical trials as topic,3
 durable response,3
 molecular pathology,2
LC,2
 sickle cell disease,2
 mTORC1,2
 programmed cell death protein 1,2
 elderly,9
 Triple negative breast cancer,5
 P-glycoprotein,3
 Cell biology,2
 adrenocortical carcinoma,3
drug resistance,3
JNK,3
Gene expression,2
 leptomeningeal metastases,2
Anti-PD-1,4
 artesunate,2
 immune microenvironment,2
 Cell cycle arrest,8
 multiple primary lung cancer,2
 Tumor progression,3
DLEU2,2
 Cellular apoptosis,2
 Follow-up,3
ROS,4
 tyrosine kinase inhibitor,15
 Palbociclib,3
 Human papilloma virus,2
 Cytology,2
Bone metastasis,6
 Endocrine therapy,2
 OS,3
 Spinal metastases,2
 spread through air spaces ,2
 follow-up,2
 Ionizing radiation,4
 cohort studies,3
 iron oxide nanoparticles,2
 malignant pleural mesothelioma,6
18F-fluorodeoxyglucose positron emission tomography/computed tomography,2
 cancer treatment,2
 FGFR,3
 PSA,2
 susceptibility,3
 iNOS,2
 PRAD,2
 targeted therapy,26
 flow cytometry,4
Non-small cell lung cancer,35
 Survey,3
 metabolomics,5
 quality of life,16
 cancer,91
 Central nervous system,2
 Early stage lung cancer,2
Anti-PD-1/PD-L1 antibody,2
 Risk stratification,2
FDG,2
 MVA,2
 Welding,2
 Screening,15
Elderly patients,2
 microRNA sponge,2
 Non–small-cell lung cancer,7
3-dioxygenase,2
 curcumin,2
 PET/CT,17
 clinical practice,5
 KPS,2
breast cancer,13
 mediastinal tumor,2
Abscopal effect,4
 Real-world data,2
 Lung injury,4
 registry,2
 therapy resistance,3
Carcinoma,11
 CD8,2
 kidney renal papillary cell carcinoma,3
 Platinum,3
irAEs,3
 Crystal structure,2
 DNA damage,8
Brain metastasis,10
 chemosensitizer,2
Lobectomy,5
 tobacco smoke,2
 Prognostic factor,7
 palliative care,10
 obesity,8
 Proliferation,18
FDG-PET,3
 KRAS mutation,4
 nedaplatin,2
 Metabolism,6
fatigue,2
 Lung toxicity,2
 Aspirin,2
 organ-on-a-chip,2
 pencil beam scanning,2
 radiation therapy,8
CSCs,2
 radiosurgery,3
 Pulmonary lymphangitic carcinomatosis,2
 miR-330-5p,2
 SUV,3
 Immune checkpoint inhibitor,15
 Coronavirus disease 2019 ,2
 exhaled breath condensate,3
 protocols & guidelines,2
Fluorescence in situ hybridization,2
 TTF-1,5
 genotoxicity,2
 Erlotinib,9
 Paclitaxel resistance,3
immune checkpoint inhibitors,3
 MYC,2
 stereotactic body radiation therapy ,2
 Cell cycle,4
 competitive endogenous RNA,2
 wedge resection,2
 prediction,4
 metastasis,82
 pancreatic ductal adenocarcinoma,3
 Cancer stem cells,2
Adjuvant chemotherapy,4
 prognostic model,3
 Extracellular matrix,3
 cancer survival,3
 chitosan,3
 chronic obstructive,2
 Prognostic markers,2
 Pandemic,4
 Corticosteroids,2
 cigarette,2
 Biomarker,9
 cytotoxicity,12
 innate immunity,5
 Retrospective study,2
 WGCNA,2
 Metastatic cancer,5
 severe acute respiratory syndrome coronavirus 2,3
 Broncoscopia,2
Exosome,2
 population attributable fraction,2
 chronic obstructive pulmonary disease,7
 long noncoding RNA,5
 synthesis,2
 sarcoma,3
 complication,2
 Rural,2
 tumor recurrence,3
 Nanoparticles,6
 neoplasms,6
 miR-142-5p,2
 anxiety,2
 Reactive oxygen species,8
 Wnt/β-catenin signaling,2
 lung nodule,7
 mechanisms,2
 RNA-seq,3
Multidisciplinary care,2
 super-enhancer,2
Epithelial-mesenchymal transition,4
 microRNA,20
 propensity score matching,3
Neoplasms,2
 Methylation,7
TP53,2
 MU,2
 THYM,2
ALK inhibitor,2
 molecular dynamics simulation,2
LCNEC,2
 hematologic neoplasms,2
lncRNA,2
Case report,11
 pulmonary infection,2
 bone metastases,2
 tumor suppressor gene,2
 oxidative phosphorylation,3
 tumor-infiltrating,3
 bladder urothelial carcinoma,2
 nanomedicine,4
EORTC QLQ-C30,2
 Neuroendocrine tumor,3
 tumor mutational burden,4
Lung cancer surgery,2
 VATS,12
Crohn's disease,2
 Video-assisted thoracic surgery,2
 Brigatinib,2
FoxM1,3
 Pt,2
Acute lung injury,2
 colorectal adenomas,2
 Separation surgery,2
SEMS,2
IL-10,2
 Multidrug resistance,5
 immune-related adverse events,8
 lymph node metastasis,7
 GRP78,2
 Radiation pneumonitis,2
FOXM1,2
 fatigue,2
 Large cell neuroendocrine carcinoma,2
18F-FDG,8
 resistance mechanism,4
Anti-inflammatory,2
 medical oncology,2
 Body mass index,2
 resistance mechanisms,3
 Pathogenesis,3
LUCAT1,3
 quality management,2
 Signal transduction,2
Advanced breast cancer,2
 positron emission tomography,5
 amplification,3
 Pulmonary fibrosis,7
 classification,3
 positron emission tomography/computed tomography,2
 procalcitonin,2
 anaplastic lymphoma kinase,6
LDCT,3
MDCT,2
 dioscin,2
 SBRT,20
3D printing,2
China,4
 cell migration,4
 VEGF,8
 pembrolizumab,26
4DCT,2
 Computer-aided diagnosis,2
 pneumonectomy,7
 carboplatin,2
16S rRNA sequencing,2
Companion diagnosis,2
 knowledge-based planning,2
 Solid tumor,3
 indocyanine green ,3
 ERK,2
 risk factors,15
ADCC,2
case report,2
 salvage surgery,3
 Prognostic factors,3
exosome,2
 MYH9,2
 non-small cell lung carcinoma,8
Circulating tumor DNA,2
HPV,3
 cell therapy,2
 atherosclerosis,3
ALK inhibitors,5
 immune checkpoint inhibitor ,2
 FAK,2
 PI3K/AKT/mTOR,2
Alternative splicing,2
 angiosarcoma,2
 nuclear medicine,2
 diagnostic imaging,2
 Migration and invasion,2
 Response Evaluation Criteria in Solid Tumors,2
 Cell proliferation,5
 Malignant mesothelioma,3
HIF-1α,3
2H-azirines,2
 SCLC,12
 myocardial infarction,2
 Expectations,2
 invasion and metastasis,2
 NLST,2
 precision medicine,9
 immune cell,2
 cancer progression,2
 neuroendocrine,3
 Cost-effectiveness analysis,4
 radiotherapy,41
 Next generation sequencing,2
 metformin,6
 HER2,6
 malignant pleural effusion,7
CDK4,2
 carcinogenesis,6
 Incidence,11
 cohort,3
Nomogram,2
 mRNA,3
 immuno-oncology,2
 brain metastases,9
 Squamous cell lung cancer,2
 COPD,9
 inhibitor,2
cisplatin,3
 chronic respiratory diseases,2
preventive medicine,2
T790M,2
 pan-cancer,8
 cystic fibrosis,2
 crizotinib,10
 Pulmonary tuberculosis,2
 small cell lung carcinoma,4
SABR,3
 protein expression,2
 disease progression,2
carboplatin,2
 epigenetic regulation,2
CYLD,2
chest imaging,2
 COVID-19,35
 ultrasound,2
 Radiation,10
 serum exosomes,2
 xenograft model,2
 systematic literature review,2
 Risk assessment,5
 estrogen receptor,2
elderly,2
 carfilzomib,2
 tumour microenvironment,4
Colorectal cancer,10
 LncRNA,2
 Cisplatin,9
 cytoskeleton,2
 Radiation oncology,2
 alternative splicing,5
 case report,14
 NF-κB,15
 osimertinib,25
 miRNA-disease associations,2
 tumor angiogenesis,2
circular RNA,2
 EBUS-TBNA,3
 ctDNA,5
 Sclerosing cholangitis,2
 Indoor radon,2
 MET,9
bevacizumab,2
 thymoma,3
 infection,5
 DNA damage response,2
 CpG island,2
 skin cutaneous melanoma,2
 Oncogene,3
 predictive biomarkers,2
clinical assessment,2
 Immune checkpoint inhibitors,14
 HK2,2
 immunohistochemistry ,3
 Cancer stem cell,2
 microenvironment,3
 Cáncer de pulmón,3
 antiproliferative activity,2
 Notch1,2
 FDG,2
 etoposide,4
angiogenesis,10
 antitumor,3
TAMs,3
Antibody,2
ER stress,3
 depression,9
 toxicity,11
 Lipidomics,3
 human immunodeficiency virus,2
 ubiquitination,4
 Savolitinib,3
 Epithelioid sarcoma,2
 computational biology,2
 research,4
 Epidermal growth factor receptor,17
 characteristics,2
 Lung cancer,318
 Nonsmall cell lung cancer,3
 targeted therapies,3
 long non-coding RNAs,4
 Lung cancer surgery,2
 Re-biopsy,3
 drug therapy,4
 Planning target volume,2
 Multidetector computed tomography,4
 small cell,2
 influenza,5
IHC,3
 head and neck cancer,4
 Phase I,2
 Tomography,9
 phagocytosis,2
 liver metastasis,5
 response,3
 pd-L1,2
 cancer prognosis,2
 Serum,3
 Cancer incidence,3
 STAD,2
 endobronchial ultrasonography,2
 T cell,3
cancer immunotherapy,2
 Thoracic cancer,2
 X-ray,2
Biopsy,4
 epidermal growth factor receptor tyrosine kinase inhibitor,3
 Lung cancer risk,3
 Checkpoint inhibitors,2
 Multidisciplinary team,2
 TP53,13
 disparities,2
 non-Hodgkin lymphoma,3
 Macrophage,3
 single nucleotide polymorphism,4
 Sintilimab,2
 Welding fumes,2
 Lung nodules,2
 Lung neoplasms,56
 PSMA,2
 Children,2
 lung cancer screening,11
 blood,3
Pulmonary segmentectomy,2
Chemoradiotherapy,8
 video-assisted thoracoscopic surgery,3
 testicular cancer,4
 small-cell lung carcinoma,3
 circRNAs,3
 YY1,2
chronic obstructive pulmonary disease,4
 cohort study,2
 Computed tomography,15
 Nrf2 inhibitor,2
 Tregs,2
 prognostic nutritional index,2
 tumor immunity,2
 lung cancer surgery,3
 Neuroendocrine differentiation,2
 Lifestyle,3
 Health-related quality of life,4
 prognostic value,2
 safety,9
 Terminal cancer,2
 Encephalitis,2
 oligometastasis,2
 cytochrome P450,2
Anti-PD-1 antibody,2
 Recurrence,12
KRAS mutation,2
 Smoking cessation,3
SEER,12
 Survival prognosis,2
TMB,3
CRC,3
 Pancreatitis,3
 immunocytochemistry,2
 Oxaliplatin,2
 TGFβ,2
Cytokines,2
3H,2
 SARS-CoV,5
Cancer,77
AXL,2
 Neddylation,2
 Physical activity,3
 PP2A,2
 Copy number alteration,2
 NRF2,9
 mobile health,2
 Sensitivity,2
 hepatocellular carcinoma,9
 immune modulation,2
 Antiproliferative activity,2
 apoptosis,56
 paclitaxel,13
Cancer incidence,2
 LUSC,5
Cancer screening,4
Doxorubicin,3
 microarray,4
 epidermal growth factor receptor ,7
 TP53 mutation,3
 Thoracic malignancies,2
 Prevalence,4
Angiogenesis,11
 human,2
 lymph node,6
 Stereotactic body radiotherapy,4
 docetaxel,5
Cell-free DNA,3
 LDH,2
 Risk,3
MM,2
BM,5
 prodrug,2
 localization,2
 caveolin-1,2
4T1,2
 Mice,2
 minimal residual disease,2
 Colorectal cancer,18
 standardized mortality ratio,2
 CESC,2
 viability,2
Lewis lung carcinoma,3
 Pancreas,2
 FTIR,2
 Liver metastasis,6
 Urothelial carcinoma,3
Cell cycle,2
 Stage III,5
 Meta-analysis,32
 statistics & research methods,2
 fine particulate matter,2
 Ceritinib,4
CD36,2
 cancer therapy,7
Clinical trial,2
 quantitative proteomics,2
 Pericytes,2
NF-κB,2
 Oral cancer,3
 brain metastases ,2
 molecular docking,8
 Rehabilitation,2
 breast cancer,40
 Malignancy,8
antitumor activity,2
 cigarette smoking,2
Lung metastasis,2
 morphology,2
 triple-negative breast cancer,7
 DNA binding,2
Diagnostic imaging,3
 Anticancer,2
 Immune related adverse events,2
 LDHA,2
Lung adenocarcinoma,17
 LC,2
Complications,2
 immune-related genes,3
 Pathophysiology,2
 Diagnostic imaging,4
 tyrosine kinase inhibitors,7
 Multiple myeloma,2
 health economics,2
 Inhibitor,3
 HDAC,5
 Dissociation constant,2
 biopsy,3
 Nintedanib,2
 insulin-like growth factor,2
 telemedicine,2
 Chemotherapy,27
 Radiogenomics,2
bal,2
C00,6
 Genetics,2
 Indigenous,2
Artificial intelligence,4
 Sarcoma,4
 miR-145,3
 acquired resistance,3
Cisplatin,3
 mutation,14
 margins,2
 LKB1,3
 tumorigenesis,7
Liquid biopsy,2
 Febrile neutropenia,2
 avelumab,2
 Lung diseases,2
 Carcinoma,8
 Cancer cachexia,2
Europe,2
ICG,3
 mouse model,3
 Coronavirus,13
 Gemcitabine,5
 cytokine storm,4
Advanced lung cancer inflammation index,3
 Indocyanine green,2
 artificial intelligence ,2
bioinformatics,4
 Risk factors,10
LUAD,13
 circulating tumor DNA,6
 TNF-α,2
 CS,3
KRAS,13
Circular RNA,4
 Lymph nodes,2
Hepatocellular carcinoma,3
 Nomogram,17
Treg,2
 small cell carcinoma,3
 Non-small cell lung cancer,140
 RAS,3
Bevacizumab,7
 minimally invasive adenocarcinoma,2
 phosphoproteomics,2
 fibroblast,3
 TIGIT,2
 diagnosis,23
 prostate cancer,13
VEGF,3
 Thoracic surgery,7
Asthma,5
 erlotinib,10
 PET-CT,8
Aspirin,2
 navigational bronchoscopy,4
 Severe acute respiratory syndrome coronavirus 2,3
 Transfection,2
 outcome-based-contracting,6
 outcomes,11
 Molecular pathology,2
 β-Catenin,3
 Poly,2
IMPT,2
 lipiodol,2
Chinese patients,2
ABCG2,3
EMT,25
Aryl hydrocarbon receptor,3
 molecular imaging,3
 clinical trials,4
 neuroendocrine neoplasms,3
Cancer invasion,2
 reactive oxygen species modulator 1,2
VATS,10
 symptoms,2
 MUC1,2
 cervical cancer,2
 natural killer cells,2
 Cytotoxic,3
antineoplastic agents,2
 spirometry,5
 Tumor,5
 Literature review,2
 pulmonary metastases,2
Cervical cancer,3
 Necrosis,3
 robotic,2
 bone metastasis,6
 pulmonary resection,3
 immunotherapy,126
 Liposome,2
 PD-L1 inhibitors,2
 neurotoxicity,2
 ipilimumab,2
 prognosis,150
 protein synthesis,2
Adenosquamous carcinoma,2
EGFR TKI,4
 Gene expression,8
 Invasion,10
 N6-methyladenosine,3
 deep inspiration breath hold,2
 doxorubicin,5
Antiangiogenic therapy,2
cancer intervention,2
 molecular profile,2
 IL-1β,2
Breast cancer,31
chronic disease,3
 Radiothérapie,2
 Trastuzumab,2
III,2
 Cardio-oncology,3
chemotherapy,11
 transcription,2
 fine-needle aspiration cytology,2
 programmed death-1 ,2
 interferon,4
 Radon exposure,3
 SARS,3
 Medical Biochemistry,2
 Lung adenocarcinoma ,7
 rechallenge,2
 tumor evolution,5
 radioimmunotherapy,4
−,2
 predictive biomarker,4
 glycolysis,10
 SARS-CoV-2,46
 second cancer,2
Cancer metastasis,3
 Cell death,2
 risk prediction,2
EGFR TKIs,2
 molecular typing,2
 Lung cancer incidence,2
 histology,3
 Catechin hydrate,2
 miR-29a,2
EGFR-TKIs,5
 RhoA,2
asthma,3
 Pulmonary disease,2
 Pulmonary,2
 rapid on-site evaluation,3
 cholesterol,2
 lung biopsy,2
 viral infection,2
 stereotactic body radiotherapy,9
 Epstein-Barr virus,2
 NLRP3 inflammasome,3
 inhalation,2
 cancer patients,3
 review,5
 first-line,2
 SEER,13
 Metastatic,2
 non-small-cell lung,9
 MMP-9,2
 nephrotoxicity,2
Asbestos,2
 plasma,2
 Emergency surgery,2
 Intersegmental plane,3
 harmonization,2
 lymphatic metastasis,2
 lymph node dissection,2
 D-dimer,2
 phosphorylation,2
 patient-reported outcomes,2
 S100A14,2
 machine learning,12
 TGF-β1,8
 Phytochemicals,2
 MicroRNAs,2
 PDAC,4
Cryptotanshinone,2
 extracellular matrix,5
 cancer-associated fibroblast,3
 multiple myeloma,4
Early detection of cancer,2
 anticancer agent,2
 D40,7
dexmedetomidine,2
 Hypoxia,7
 lung squamous cell carcinoma,17
 Stemness,2
ICI,5
 precision oncology,2
 drug delivery,8
DNA repair,3
Gefitinib,2
Chinese,4
 Anaplastic lymphoma kinase,4
 pegfilgrastim,2
 malignant melanoma,2
 NSCLC,215
CT imaging,5
 miR-376a,2
 nivolumab,28
 lung transplantation,3
 synergy,2
 drug discovery,2
 Ubiquitination,2
Chemoradiation,2
 Endobronchial ultrasound,4
Emphysema,2
 Validation,3
ACK1,2
 therapy,7
 NK cells,5
 cutaneous T-cell lymphoma,2
 Lung function,4
Non-small cell lung cancer ,25
Lung,5
 ouabain,2
 lung cancer ,4
 signal transduction,2
 protein degradation,2
 skin cancer,5
 radiation necrosis,2
 Metabolomics,3
 p16,2
 radioresistance,2
Concomitant chemoradiotherapy,2
 Pulmonary nodule,4
 Platinum-based chemotherapy,2
 psycho-oncology,2
 Tyrosine kinase inhibitors,6
 Synergism,2
 Bevacizumab,3
 Lymphoma,2
 population,2
 Locally advanced NSCLC,2
 Wnt/β-catenin pathway,3
 Prognosis,87
 Cancer cells,2
 resveratrol,2
18F-FDG PET/CT,4
 radiation,13
 pulmonary embolism,5
ADP-ribose,3
Barbituric acid,2
 immune,5
Esophageal cancer,3
 immune infiltration,7
 ground glass opacity,3
 treatment planning,2
 lungs,2
 lung cancer risk,2
 EGFR-TKIs,2
 Mesothelioma,9
 Diabetes,2
asbestos,2
 Polychlorinated biphenyls,2
EGFR mutation,19
 ARDS,2
 TMPRSS2,7
 Lung cancer screening,12
 PD-L1 expression,3
Blood–brain barrier,2
 Vital capacity,2
 Bax,2
 checkpoint inhibition,2
 microRNA-21,2
 Overexpression,2
 CR,2
 Safety,13
 randomized controlled trial,2
BAP1,5
 Compound mutation,2
SCLC,12
 clinical course,2
 OXPHOS,3
brain metastases,11
 Radiosurgery,5
 Surgical resection,2
 Exosome,2
 non-small-cell lung cancer ,3
 personalized medicine,3
Chronic obstructive pulmonary disease,4
 arsenic trioxide,2
Complication,4
 MRI,3
 lung metastasis,6
 Myelosuppression,2
biomarker,22
 primary care,2
 EBV,2
Adrenal,2
 Programmed cell death-ligand 1,2
 Cell Biology,3
 Rebiopsy,2
 Stem cells,2
 muscle wasting,2
 cytology,7
 Gefitinib,11
 part-solid nodule,2
 PD-1/PD-L1,3
 GSK-3β,2
 small cell lung cancer ,4
 Cancer cell,2
Notch signaling,2
Circulating free DNA,2
 Combination therapy,5
 Crizotinib,9
 local ablative therapy,2
 Tp53,2
 Molecular diagnosis,2
 transplantation,3
 Immune-related adverse events,5
 polymerase,2
Classification,3
 head and neck neoplasms,3
 VMAT,3
Immunohistochemistry,2
 subtypes,2
 lobectomy,9
COPD,14
 Glioma,2
Glutaminolysis,2
 TGF-β,7
 computed tomography,12
lung adenocarcinoma,4
 trend,2
 platinum,5
TCGA,3
 Checkpoint inhibitor,2
BRCA1,2
BRCA2,2
 Biomarkers,4
 respiratory tract tumours,6
 Monoclonal antibody,4
 RB,2
ICIs,4
 synchronous,3
 Mediastinum,3
 immune-related adverse event ,2
 Stomach neoplasms,2
 arsenic,2
 chemoradiotherapy,6
 exosomal miRNA,2
 microfluidic chip,2
 sex,3
Cancer patients,2
 Staging,7
Anti-PD-1 therapy,2
AURKA,3
 deep learning,8
 SARS-CoV2,3
 cytokines,8
 proton therapy,7
 Hydrogen,2
 Drug targeting,2
lymph node metastasis,2
Bladder cancer,3
 Resilience,2
COVID-19,78
Coronavirus disease 2019,3
 Intensive care,2
 combination,4
 image-guided biopsy,2
 P-gp,3
 EGFR mutation,13
 Wound healing,2
 pancreatic ductal adenocarcinoma ,2
PDAC,2
 prevalence,2
 Pulmonary lobectomy,3
 pandemic,6
 Nicotine,2
 prognostic signature,3
 PSA test,2
 fibrosis,5
 steroids,3
 Venous thromboembolism,3
 NF-κB pathway,2
Hodgkin lymphoma,3
 transbronchial lung biopsy,2
 Immunohistochemistry,11
 Mexico,2
biomarkers,22
 PTEN,5
BRD4,2
 surgery,32
 Machine learning,14
 oligometastases,2
Checkpoint inhibitor,3
 stemness,5
computed tomography,6
 Tumor-infiltrating,2
 lung toxicity,2
 PI3K/AKT,2
 Neoplasms,10
 Radiation dose,2
Overall survival,2
LUSC,4
 ceritinib,2
 organoids,2
 health disparities,3
 overall survival,37
 miR-125b,2
 therapeutic target,7
 ROCK,2
Advanced non-small cell lung cancer,3
 Neutrophil-to-lymphocyte ratio,2
 cell biology,2
 circular RNAs,3
 photothermal therapy,2
 network,3
 prediction model,2
 Cell therapy,2
 bioinformatics,10
 oral epithelial cells,2
 treatment response,5
 atezolizumab,9
 Radiotherapy,36
Bone metastases,2
epidemiology,6
 cancer incidence,2
 circ_0074027,2
 liver cancer,3
 concordance,2
 differentiation,4
 COAD,3
 spine,2
 crazy paving,2
 niclosamide,2
 coronavirus disease 2019,3
 non-coding RNA,2
 pulmonary function,2
cell cycle,2
 Management,2
 PEG,2
 Paclitaxel,5
 Palliative care,5
 Pancreatic neuroendocrine tumor,2
 KIRC,3
Cell apoptosis,3
 meta-analysis,34
 KIRP,3
 Microtubule,2
 carcinoembryonic antigen,4
 Glycemic load,2
 cell proliferation,13
 pheochromocytoma,2
health economics,2
 expression,4
 smoking,25
 platelet-to-lymphocyte ratio,2
 non-small cell lung cancer,245
 pediatric,2
 next-generation sequencing ,3
 tumor spheroid,2
 positron emission tomography ,3
 Lung metastasectomy,3
 Molecular docking,6
 next generation sequencing ,3
 older adults,4
 Leptomeningeal metastasis,2
 miR-150-5p,2
 Leptomeningeal metastases,2
Early lung cancer,2
 SBRT ,3
 X-ray crystallography,3
 ground-glass opacity,3
 clustering,2
Endoscopy,2
 Health sciences,2
 lung colonization,2
MeSH term,2
 lysosome,2
 gemcitabine,3
stereotactic body radiation therapy,2
 gluconeogenesis,2
 mechanism,4
ALK,20
metastasis,3
 early diagnosis,5
 programmed death ligand 1 ,3
 progression-free survival,10
 Positron emission tomography computed tomography,3
EZH2,2
Brachytherapy,2
Airway obstruction,3
Cirrhosis,2
 Video-assisted thoracoscopic surgery,6
 LUAD,7
 signature,2
 interstitial lung disease,9
 biostatistics,3
 sleeve lobectomy,2
FOXL1,2
 RT,2
 Locally advanced non-small cell lung cancer,3
 immune checkpoint inhibitors ,2
 Survival,36
 stress,4
 Minimally invasive surgery,2
 TKI,6
 Autophagy,11
 Malignant peripheral nerve sheath tumor,2
Clinical trials,3
 Lung tumor,3
 Video-assisted thoracic surgery ,2
 intercellular communication,2
 infective endocarditis,2
 prognostic,7
 MDSC,2
 Thoracic,2
 Drug resistance,5
AF,2
Endobronchial ultrasound,2
Anticancer,7
 sex-determining region Y-box 2,2
 estrogen,2
 Lung carcinoma,5
 Long non-coding RNA,7
 Squamous cell,2
 Immune response,4
 Observational study,2
 ITV,2
 Registries,2
 Small-cell lung cancer,3
 Infection,2
 quality,2
 circulating tumor cell,2
 Melanoma,10
 MMP2,2
 MMP1,2
,7269
 MMP9,2
non-small cell lung cancer,5
 KRAS,11
FOXO1,3
Adaptive immunity,2
 PI3K/Akt,2
 Imaging,6
 mesoporous silica,2
 Patient-reported outcomes,6
 Qualitative research,2
 Social support,2
MPM,2
 Non-small-cell lung cancer,38
 RNA sequencing,5
 macrophage polarization,3
 Cáncer,2
meta-analysis,2
 intermittent hypoxia,3
 sepsis,6
 Pulmonary tumor thrombotic microangiopathy,2
 SRSF1,2
Biomarker,25
Covid-19,2
 PM,6
 uterine corpus endometrial carcinoma,3
 survival analysis,8
 multidisciplinary,3
 stage IV,2
 esophageal carcinoma,3
 Proteins,2
NGS,14
 patient safety,2
 Substance P,2
 drug-drug interaction,2
 Pneumonitis,3
 Surveillance,9
 minorities,2
 Molecular diagnostics,2
IL-6,2
 Case report,11
 pancreatic adenocarcinoma,3
 surgical treatment,2
 TMB,6
 tumor progression,6
 oligometastatic,3
 malignancy,6
 platelet,2
 Immune-related adverse event,7
 alanine aminotransferase,2
 p,2
 Pneumonectomy,5
anticancer activity,2
immunology,4
 effusion,2
 Breast cancer,16
 EGFR-mutant NSCLC,2
 immunohistochemistry,25
ESCC,2
 Nsclc,2
 differential diagnosis,2
 mTOR,8
 lung cancer cells,2
 Spirometry,2
 Photodynamic therapy,5
 pregnancy,2
 Shared decision-making,2
 Radiomics,18
 mesothelioma,7
RNA sequencing,4
 Pulmonary metastasis,5
Indoleamine 2,2
 survivorship,4
Heterogeneity,2
 venous thromboembolism,3
 Support vector machine,2
 oncogene,6
 Etoposide,2
 metastatic,8
 Chemoradiotherapy,3
 MALAT1,10
 colon adenocarcinoma,3
 metronomic chemotherapy,3
 PM2,6
 anticancer activity,2
 inhibition,2
 Diarrhea,3
 Thyroid carcinoma,2
 Liver transplantation,2
Autophagy,15
 Pleural effusion,3
 Depression,3
 m6A,3
 radiation resistance,2
erlotinib,2
 microRNAs,9
 microfluidics,2
 Primary health care,2
 DNA methylation,8
 SCC,2
cytotoxicity,4
 Serum biomarker,2
 Inflammation,23
 cancer screening,3
 Bone metastases,2
 HCC,2
 IMPT,3
 Connective tissue disease,2
 dermatomyositis,2
 pharmacoepidemiology,3
Advanced stage,2
 SEER program,2
 Cytotoxic activity,2
BMI,2
 cfDNA,8
 Lung squamous cell carcinoma,4
 Lymphangiogenesis,2
 pancreatic cancer,5
 STK11,3
 Therapeutic targets,2
 SKCM,2
 reactive oxygen species,4
cancer,47
 FDG PET/CT,3
 Biomedical analysis,2
Air pollution,10
 translation,3
 celastrol,2
ERβ,2
 fine-needle aspiration,3
 head and neck squamous cell carcinoma,3
 ionizing radiation,5
 health knowledge,2
 children,5
 Hyaluronan,2
Biomarkers,14
 video-assisted thoracoscopic surgery ,3
 liver resection,2
 Ornithine decarboxylase,2
 Exercise,2
 vitamin D,3
immunohistochemistry,3
Lung cancer,76
 Nrf2,5
 brain metastasis,8
 immunomodulation,3
 Multiple primary lung cancer,2
 metachronous,3
 Spinal Instability Neoplastic Score,2
 osteosarcoma,7
 RT-qPCR,2
 Synchronous second primary cancer,2
 myeloid cells,2
 FDG-PET/CT,2
 CXCR4,3
Adenocarcinoma of lung,3
 Mucins,2
 Deformable image registration,2
 Nivolumab,12
EGFR tyrosine kinase inhibitor,3
 mediation effect,2
 programmed death ligand-1,4
 respiratory motion management,2
 pd-1,3
 TKI resistance,2
 Pulmonary nodules,4
 EZH2,3
IMRT,3
 PD-1,17
 immune therapy,3
 human chorionic gonadotropin,2
 TNM staging,2
 Mediastinal staging,2
 Squamous cell carcinoma,9
 neutrophils,3
PD-L1,18
Canada,2
 tumor-infiltrating immune cells,2
c-MET,2
inflammation,3
Cost-effectiveness,2
 liquid biopsy,21
 Proton therapy,4
 economic evaluation,2
 Mitochondria,3
 Heterogeneity,2
 Magnetic resonance imaging,5
lung cancer,25
Berberine,3
 Lymph node,3
 network consistency projection,2
 leukocyte,2
 Ralimetinib,2
PD-1 inhibitors,2
 Cigarette smoking,2
Amrubicin,2
 survival,49
 colon cancer,7
Anaplastic lymphoma kinase,5
 SELEX,2
 Mammogram,2
 β-catenin,12
 DSB repair,2
 Oncology,21
 pancreas,2
ACE2,12
 monoclonal antibody,2
 Consensus,2
 Non-small cell lung cancer ,10
 PROTAC,2
 Immunity,2
 immune checkpoint blockade,5
 breast neoplasms,2
 radiation oncology,3
EGFR-TKI,7
 cancers,2
 droplet digital PCR,3
SARS-CoV-2,4
 lung cancer treatment,2
 MLC,2
 apatinib,4
4-Dihydropyridine,2
 Rare cancer,2
 non-small cell lung cancer ,34
T790M mutation,2
 lung neoplasms,48
 Idiopathic pulmonary fibrosis,4
 leukemia,2
 Brain metastasis,10
Arthroplasty,2
 surgical outcomes,2
 programmed death ligand 1,3
 resistance,12
Cardiovascular,2
 Oligometastases,2
 gefitinib,10
 Personalized medicine,2
 Lung metastasis,13
 ESCC,5
 ESCA,3
 primary pulmonary lymphoma,2
 Precision medicine,5
 biodistribution,2
Breast Cancer,2
 Pulmonary embolism,2
 platinum-based chemotherapy,7
 Gross tumor volume,2
EBUS-TBNA,3
 Mitochondrial apoptosis,2
Mendelian randomization,2
 Surgery,23
 Lung neoplasm,4
 adenovirus,2
 Ramucirumab,3
 HNSC,3
Carcinogenesis,3
 LDCT,3
brain metastasis,2
 Psychometrics,2
 paraptosis,2
 THCA,2
 gefitinib resistance,3
 biomarker,38
Autoantibody,3
Anticancer activity,3
 Peripheral lung cancer,2
Computed tomography,14
Antioxidant,2
 genetics,2
 paraneoplastic neurological syndrome,3
NEDD9,2
 Microbiome,2
 SNP,2
 neoplasm metastasis,4
 Image interpretation,2
 Vaccinia virus,2
 immunologic,2
 extracellular vesicles,10
 EGFR,35
 risk score,3
AMG510,2
 SACT,2
 Segmentectomy,9
 Positron emission tomography,9
anticancer agents,2
Coronavirus disease 2019 ,2
 stereotactic body radiation therapy,4
 CSCs,2
 next-generation sequencing,24
 Spine,2
Gemcitabine,2
 cancer stem cell,4
 MET exon 14,2
 diabetes,4
 PM10,2
 PD-L1,60
 gene set enrichment analysis ,2
 Prospective cohort study,2
 Eastern Cooperative Oncology Group,3
 thoracic surgery,21
 lung microbiome,2
 Echocardiography,2
 Shared decision making,2
PI3K/AKT,2
 lung adenocarcinomas,2
 lung adenocarcinoma ,7
 drug resistance,16
 Salvage surgery,2
HMGB1,3
 Epigenetic regulation,3
 Virus,3
 Pemetrexed,4
 Smoking,8
 Ibrutinib,2
 Non–small cell lung cancer,6
CTCL,2
 Diagnosis,10
anticancer,2
 Non-small cell lung carcinoma,7
 esophagectomy,2
 durvalumab,4
 tongue squamous cell carcinoma,2
 Esophageal cancer,2
 tomography,4
 public health,9
 nomogram,15
 tumor mutation burden,2
 nursing,2
Data mining,2
 invasive mucinous adenocarcinoma,3
 Brain,3
 bronchoscopy,6
 immune-checkpoint inhibitors,3
 MET amplification,3
NSCLC,131
 magnetic resonance imaging,2
 Tyrosine kinase inhibitor,3
 Thromboembolism,2
 complexes,5
 ubiquitin,2
Cell proliferation,3
 observational study,2
 NTRK,3
 alveolar macrophages,2
 propensity score,2
 Bronchoscopy,4
 Doxorubicin,10
 Oxidative stress,8
 Adult,3
 Ipilimumab,2
 Stereotactic ablative radiotherapy,2
 miR-4677-3p,2
 angiogenesis,12
 Prognostic biomarker,2
 texture analysis,2
 ccRCC,2
Segmentectomy,2
 invasion,28
 liposome,3
 Cardiac glycosides,2
 pulmonary nodule,6
 FOXA1,2
2D,2
 FOXO1,3
 FOXM1,2
 progression,8
Lung neoplasms,5
 TCGA,15
Asian,2
 cellular uptake,3
DNA damage,4
ABC transporters,2
 early-stage,2
 management,4
 older patients,2
 lung cancer,463
 pricing methods,7
cancer risk,2
IV,2
 ROS,15
 Renal cell carcinoma,5
 Interferon,3
 lung diseases,2
 clinical decision support,2
 bronchoalveolar lavage fluid,2
 Glycolysis,2
 EWSR1,2
 guideline adherence,3
 TRAIL,4
 PDK1,2
 Lung metastases,2
 Nausea,2
 non-small cell lung,5
 Histology,3
